Nature's pharmacopeia has always been generous to drug hunters. Gila monster venom begot diabetes treatments. Cone snail toxins now manage chronic pain. Snake peptides laid the groundwork for ACE inhibitors, the blood pressure workhorses that millions take daily. But one category of organisms—arguably the most sophisticated immune manipulators on the planet—has gone largely untapped. Parasites.
These are creatures that have spent geological timescales perfecting survival inside hostile hosts, evading immune surveillance for months or years at a stretch. Viruses that reprogram cellular machinery. Ticks that inject whole cocktails of anti-inflammatory molecules. Helminths that dampen allergic responses so effectively they've inspired fringe medical movements. The question a small cohort of biotechs is now asking: what if we stopped treating parasites as enemies and started treating them as laboratories?
Enter Ditto Bio, a three-person team fresh out of Y Combinator's Winter 2026 batch. The San Francisco startup is building what it describes as an "evolutionary drug discovery platform"—essentially a computational engine to mine parasite genomes for immunomodulators, then map those proteins to clinically validated human targets using AI. It's an audacious premise. Also an untested one, at least in any publicly disclosed preclinical dataset. But the timing may be right. As autoimmune therapeutics shift from chronic suppression toward curative or disease-modifying interventions—CAR-T cells, antigen-specific tolerance platforms, FcRn antagonists—Ditto is wagering on a third route: precision biologics inspired by millions of years of evolutionary arms racing.
Whether that bet pays off is far from certain.
The Market Ditto Is Entering
Autoimmune therapeutics remain a juggernaut. IQVIA's Global Medicine Use Trends 2026 report, released earlier this year, pegged immunology as one of the top growth drivers globally, with oncology, immunology, and diabetes/obesity collectively accounting for 43% of pharmaceutical value in 2025. But beneath the topline numbers, the category is under strain. Biosimilar competition is accelerating—the FDA rolled out streamlined approval pathways for copycat biologics on March 10, 2026—and payers are increasingly resistant to therapies that manage symptoms indefinitely without addressing root causes.
Meanwhile, a new generation of modalities is gaining clinical momentum. CD19-targeted CAR-T therapies, originally designed to obliterate blood cancers, are showing surprising durability in autoimmune conditions. Bristol Myers Squibb presented Phase 1 data from its BREAKFREE-1 study at ACR Convergence 2025, covering 71 patients across systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathies. Kyverna Therapeutics is targeting a first BLA submission in the first half of 2026 for miv-cel in stiff-person syndrome. Cabaletta Bio reported positive updates for rese-cel at the same ACR meeting.
Johnson & Johnson's nipocalimab—an FcRn antagonist—landed Breakthrough Therapy Designation for Sjögren's disease in November 2024 and Fast Track Designation for SLE in January 2026. Lancet-published Phase 2 data from October 2025 showed significant reductions in disease activity. Novartis' ianalumab, which targets BAFF receptor, secured its own Sjögren's BTD on January 16, 2026.
The patient population is substantial. A 2025 JCI Insight study put U.S. autoimmune prevalence at roughly 4.6%, translating to approximately 15.4 million people based on 2022 population estimates. Yet for all the firepower being thrown at the space—engineered T cells, nanobodies, bispecific antibodies—the underlying discovery toolkit has remained relatively narrow. Mostly synthetic small molecules. Mostly engineered or humanized proteins derived from human templates.
That's the opening Ditto is targeting.
Why Now?
Three developments are converging to make parasite-derived drug discovery more than a thought experiment.
First: AI-driven structural biology has crossed a threshold. AlphaFold 3, published in Nature in May 2024, can predict interactions across proteins, nucleic acids, ligands, and glycans with accuracy that was unimaginable five years ago. Ditto's platform leans heavily on this capability, using computational methods to map parasite-encoded proteins to human immune targets and then rank those interactions by clinical relevance. In a blog post the company published on March 2, 2026, the team described analyzing roughly 10,000 proteins from human-infecting viruses, cross-referencing them against a 2019 landscape of autoimmune targets. The result: when viral targeting frequency was factored in, TNF—arguably the most drugged target in immunology—jumped from #82 to #12 in prioritization for rheumatoid arthritis.
The TNF example is telling. Viral TNF inhibitors, such as poxviral decoy receptors and TNF-binding proteins, latch onto human TNF with high affinity. Mechanistically, they parallel etanercept (Enbrel), the blockbuster biologic that's been on the market since 1998. The difference? Enbrel is a human-engineered fusion protein. Viral TNF antagonists have been refined over millions of years of host-pathogen warfare. That evolutionary pedigree may—or may not—translate to advantages in safety, specificity, or durability. No one knows yet.
Second: there's growing appreciation that parasites evolved not just to evade immunity, but to do so with surgical precision. Tick saliva contains chemokine-binding proteins called evasins, which sequester inflammatory chemokines with remarkable selectivity. Preclinical studies from the 2019–2023 period explored evasins in inflammatory disease models, though no approved drugs have emerged. Helminth-derived molecules like ES-62 and hookworm AIP-2 showed anti-allergy and anti-inflammatory effects in older animal models. The challenge has always been translating whole-organism effects—often inconsistent or murky in human trials—into defined, scalable therapeutics.
Which brings us to the third shift: a willingness to abandon the crude helminth therapy playbook. Clinical trials of live-organism approaches, most notably Trichuris suis ova (pig whipworm eggs) in inflammatory bowel disease, stumbled badly. A 2013 Phase 2 trial in Crohn's disease failed to meet endpoints. Subsequent studies showed inconsistent signals. Ditto's thesis is that isolating and engineering specific parasite proteins sidesteps the safety and variability pitfalls of live organisms while preserving the immunomodulatory precision.
In theory.
What Ditto Actually Is
The company remains early-stage, to put it mildly. No disclosed funding beyond Y Combinator participation. A team of three. A single technical blog post as public-facing evidence. But the founding team brings heavyweight scientific credentials. CEO Dennis Sun holds a PhD from UC Berkeley with a background in evolutionary and developmental biology. CSO Adair Borges completed a PhD at UCSF, served as a Miller Fellow at UC Berkeley, and has over 50 publications in journals including Cell and Science; she co-invented patents related to anti-CRISPR systems. CTO Emily Weiss, a UC San Diego PhD, brings computational biology and high-throughput sequencing expertise from stints at DuPont and Illumina.
The platform hinges on AI-driven target mapping paired with a human tissue biobank designed to profile immune memory against parasite proteins—essentially an immunogenicity de-risking strategy. Ditto's website lists an expansive disease scope: rheumatoid arthritis, eczema, IBD, psoriasis, systemic lupus erythematosus, allergic asthma, Crohn's, multiple sclerosis, type 1 diabetes, kidney autoimmune disease, ulcerative colitis, celiac disease, vitiligo, Hashimoto's, and Graves' disease.
The ambition is sweeping. The execution remains entirely theoretical.
Elsewhere in the immune-reprogramming space, companies are pursuing related but distinct strategies. Parvus Therapeutics inked a collaboration with AbbVie in March 2024 to develop IBD therapies using its Navacim antigen-specific Treg expansion platform. COUR Pharmaceuticals raised a $105 million Series A in January 2024 and maintains a longstanding partnership with Takeda in celiac disease; on January 28, 2026, the company published new mechanistic data in Science Advances describing its tolerizing immune-modifying nanoparticles. GentiBio is engineering regulatory T cells for autoimmune applications, with multiple platform updates throughout 2025.
These are tolerance-inducing or cell-based approaches. Ditto's angle—precision biologics sourced from parasites—sits somewhat apart. Perhaps closer conceptually to conventional antibody engineering, but with a starting library drawn from an entirely different evolutionary branch. The question is whether "nature's drug developer," as the company frames it, can deliver molecules that outcompete human-designed scaffolds on safety, efficacy, or manufacturability. Or whether immunogenicity and developmental headaches will sink the approach before it reaches the clinic.
Regulatory Headwinds
Any parasite-derived biologic will face withering immunogenicity scrutiny. FDA and EMA guidance on immunogenicity assessment of therapeutic proteins remains the regulatory foundation, with risk-based strategies and validated anti-drug antibody assays expected as standard. For proteins that originated in non-human organisms, humanization or de-immunization engineering will almost certainly be mandatory. Ditto's tissue biobank concept—profiling which parasite proteins the human immune system has already encountered—could theoretically mitigate immunogenicity risk. But that's speculation until clinical data arrive.
Manufacturing and CMC comparability standards will apply in full. The FDA's dose-finding reforms under Project Optimus are reshaping early clinical trial design across novel biologics, which may influence how parasite-derived candidates navigate Phase 1. And while biosimilar policy is easing market access for existing biologics, novel first-in-class immunomodulators face a different calculus: they must demonstrate meaningful differentiation in a crowded, high-bar competitive landscape.
Reimbursement adds another wrinkle. CAR-T therapies in oncology carry list prices ranging from roughly $373,000 to $633,000 per infusion, with total episode costs often exceeding $500,000 according to recent commercial payer data. Cell and gene therapy reimbursement frameworks for autoimmune indications remain fragmented across Medicare, Medicaid, and commercial plans, though policy shifts in the FY2026 IPPS may affect provider economics. If parasite-derived biologics can be positioned as chronic therapies rather than one-time curative interventions, the reimbursement path might be smoother—but the competitive pressure from biosimilars will be correspondingly fiercer.
Precedent, Sort Of
The idea of mining evolution's toolkit isn't new. Exenatide, derived from Gila monster exendin-4, won FDA approval in 2005 and helped pave the way for GLP-1 receptor agonists, now a multi-billion-dollar category. Ziconotide, sourced from cone snail conotoxin, treats severe chronic pain. Captopril's development drew inspiration from Brazilian pit viper peptides. Eptifibatide and bivalirudin trace their mechanisms to rattlesnake and leech molecules, respectively.
But those successes emerged from venoms and toxins—offensive biochemical arsenals evolved to kill or paralyze. Parasites represent a different evolutionary domain: organisms optimized not to destroy, but to persist. Often for years. Inside a host that's actively trying to kill them. That may translate to gentler, more durable immune modulation with fewer off-target effects. Or it may mean molecules with structural complexity or delivery requirements that make drug development prohibitively difficult.
It's worth noting that whole-organism helminth therapy—the most direct precedent—mostly flopped. Trials in Crohn's, ulcerative colitis, and multiple sclerosis showed mixed or negative results. The hope is that isolating specific proteins avoids the variability and safety issues of live parasites. But that's an assumption, not a proven strategy.
What Happens Next
The autoimmune therapeutics market is undergoing a fundamental reorientation from suppression to resolution. A February 2026 perspective in Nature Reviews Drug Discovery acknowledged the promise of CAR-T in autoimmunity while outlining translational hurdles: toxicity management (though cytokine release syndrome appears milder than in oncology), logistical complexity, durability questions, and trial design challenges. Preliminary economic analyses, including a January 2026 Journal of Rheumatology study on allogeneic CAR-T in SLE, suggest potential for dramatic cost reductions—over 90% in direct costs in early cohorts, though the data remain limited and speculative.
Ditto's evolutionary angle could slot into this landscape as a middle path. Biologics with the precision and scalability of conventional antibodies, but with scaffolds optimized by natural selection rather than rational design. That's the pitch, anyway.
For investors and industry watchers, Ditto's trajectory will test several hypotheses at once. Can AI-driven parasite genome mining deliver clinically differentiated leads faster than traditional antibody discovery platforms? Will immunogenicity prove manageable, or will regulatory agencies balk at non-human protein scaffolds? And perhaps most critically, can a three-person team with no disclosed pipeline assets or preclinical data yet compete in a therapeutic area where biosimilars are commoditizing existing biologics and cell therapies are rewriting the curative playbook?
The answers won't arrive quickly. Drug discovery timelines stretch across years, sometimes decades. Ditto has yet to publish peer-reviewed validation of its platform, let alone advance a molecule into IND-enabling studies. But the company's emergence at this moment—as payers squeeze chronic therapies, as curative modalities gain momentum, and as AI reshapes what's computationally feasible—suggests the parasite-mining thesis will at least get a fair hearing.
Whether it becomes the next chapter in natural product drug discovery or a cautionary tale in the archives of ambitious biotech bets is anyone's guess. What seems certain is that the autoimmune landscape is in flux, the old playbook is being rewritten, and unconventional approaches now have room to run.
Parasites as drug factories? Stranger things have worked.
